^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

Published date:
11/09/2021
Excerpt:
TJ-CD4B (ABL111) is a novel CLDN18.2 dependent 4-1BB bispecific agonist antibody that induced T cell activation and memory response in tumor with CLDN18.2 expression, leading to a strong anti-tumor activity in vivo. 
DOI:
10.1136/jitc-2021-SITC2021.702